A Phase 1b, Open Label Study of the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of 100 mg Clemizole Hydrochloride Administered Orally Twice a Day for 28 Days Immediately Prior to Initiation of Treatment With HCV Standard of Care Therapy in Treatment-Naive Subjects Chronically Infected With HCV.

Trial Profile

A Phase 1b, Open Label Study of the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of 100 mg Clemizole Hydrochloride Administered Orally Twice a Day for 28 Days Immediately Prior to Initiation of Treatment With HCV Standard of Care Therapy in Treatment-Naive Subjects Chronically Infected With HCV.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Feb 2011

At a glance

  • Drugs Clemizole (Primary)
  • Indications Hepatitis C
  • Focus Pharmacodynamics
  • Acronyms CLEAN-1
  • Most Recent Events

    • 25 Feb 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
    • 25 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Aug 2009 According to an Eiger BioPharmaceuticals media release, the first patients have been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top